证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20151214 | --- | --- | --- | |---------------------------|--------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 调研单位 | | 国联证券股份有限公司（刘生平赴公司调研） | | 时间 | 2015 年 12 月 14 | 日（上午 10:00—11:00 ） | | | | 浙江省温州市永嘉县瓯北镇东瓯工业区园区大道迦南科技一楼 | | 地点 | 会议室 | | | 上市公司接待 | 副总经理兼董秘：陈永兴 | | | 人员姓名 | 董事办工作人员：晁虎 | | | 投资者关系活 动主要内容介 | | 一、公司作 ...

Group 1: Strategic Development - The company has established a "three-step" strategy focusing on "single machine equipment - complete line equipment - big health industry" [2] - Future strategic positioning is as a "solid preparation overall solution provider" and layout in the big health industry, with a development approach of "one body, two wings, six drives" [2] - The "one body" focuses on health value and building a big health ecosystem; the "left wing" integrates the solid preparation line with upstream and downstream industry chains [2] Group 2: Fundraising and Investment Plans - The company plans to use funds raised from the non-public offering for three projects: intelligent traditional Chinese medicine extraction production line, pharmaceutical equipment industrial 4.0 experimental center, and supplementing working capital [2] - The company aims to accelerate the economic benefits of the fundraising projects according to the usage plan [2] Group 3: New Company Establishment - The establishment of Guangzhou Canaan Mit Intelligent Packaging Equipment Co., Ltd. focuses on new generation intelligent bottle filling lines, including various packaging machines [3] - This investment will enhance the company's product range and improve comprehensive service capabilities to meet customer demands [3] Group 4: Employee Stock Ownership Plan - The company held a board meeting on September 29, 2016, to approve the restricted stock incentive plan to enhance management efficiency and stabilize the management structure [3] - The incentive plan is currently being implemented in an orderly manner [4]

证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20191211 | --- | --- | --- | |--------------|------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ | 新闻发布会 □路演活动 | | 动类别 | □ 现场参观 | | | | □其他 | | | 调研单位 | | 杭州萧山农商基金管理有限公司：马伟俊（基金经理）、李志 | | | | 杰（基金经理）、盛江宏（业务副总） | | 时间 | 2019 年 12 月 | 11 日下午 | | 地点 | 公司会议室 | | | 上市公司接待 | 副总经理兼董秘：晁虎 | | | 人员姓名 | 董事办工作人员：李健 | | | 投资者关系活 | 一、公司基本情况介绍； | | | 动主要内容介 | | | | 绍 | 二、互动问答环节： ...

证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20210521 | --- | --- | |--------------|-----------------------------------------------------------------------------------| | | | | | 特定对象调研 □ 分析师会议 | | | □ 业绩说明会 | | 投资者关系 | 新闻发布会 □ 路演活动 | | | | | 活动类别 | | | | | | 参与单位 | 中庚基金管理有限公司：季国峰（研究员） 上海南土资产管理有限公司：黄文睿（研究员） | | 时间 | 21 日下午 | | 地点 | 公司一楼会议室 | | 上市公司接 | 总经理：方正 | | 待人员姓名 | 副总经理兼董秘：晁虎 证券专员：李健 | | | 一、公司基本情况介绍； | | | 二、互动问答环节 | | 投资者关系 | 年下半年以来行业内的几家公司订单同步好转，背后的 | | 活动主要内 | 原因是什么？ | | 容介绍 | 答：其实整个制药装备市场工业产值一 ...

Group 1: Company Overview - The main business of the company is pharmaceutical equipment, recognized as a leading provider of intelligent factory solutions for solid preparations in China [2] - The business segments include solid preparation intelligent factory, biopharmaceutical innovative water equipment, pharmaceutical liquid system engineering, smart logistics, and pharmaceutical R&D services [2] Group 2: Financial Performance - The gross margin of the pharmaceutical equipment segment improved significantly in the first half of the year due to increased R&D investment and optimized supply chain efficiency [3] - As of June 2021, the company had contract liabilities of approximately 420 million [5] Group 3: Market Strategy and Growth - The company focuses on maintaining a leading advantage in technology and market share in traditional strong areas like solid preparation and powder process equipment, while also expanding into biopharmaceuticals and smart logistics [3] - The domestic market is expected to grow due to increasing industry concentration and demand for high-end imported products [5] Group 4: Customer Base and Orders - Major clients include leading pharmaceutical companies such as Sanofi, Novartis, and Pfizer, among others [4] - The company anticipates a strong order growth in the next 3-5 years driven by domestic and international market opportunities, particularly in the biopharmaceutical sector [5] Group 5: Impact of COVID-19 - The pandemic has created both opportunities and challenges, with increased demand for certain products but disruptions in international business activities [4]

证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20211216 | --- | --- | --- | |--------------|-------------------------------------------|----------------------------------------------------------------| | | | | | | 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系 | □ 新闻发布会 | □ 路演活动 | | 活动类别 | □ 现场参观 | | | | □ 其他 | | | | 姓名 | 单位 | | | 秦乾一 | 南方基金管理股份有限公司 | | 参与人员及 | 任逸哲 | 中欧基金管理有限公司 | | 单位 | 马云涛 | 西南证券股份有限公司 | | | 韩盟盟 | 平安证券股份有限公司 | | | 彭天阳 | 光大证券股份有限公司 | | 时间 | 2021 年 12 月 16 | 日下午 | | 地点 | 一楼会议室 | | | 上市公 ...

证券代码：300412 证券简称：迦南科技 编号：20220722 | --- | --- | --- | --- | |-----------------------|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|----------------| | | | | | | | 特定对象调研 | □ 分析师会议 | | | | □ 媒体采访 | □ 业绩说明会 | | | 投资者关系 | □ 新闻发布会 | □ 路演活动 | | | 活动类别 | □ 现场参观 | | | | | □ 其他 | | | | 参与人员及 | 姓名 | 单位 | | | | 张楠 | 中泰证券股份有限公司 | 医药行业分析师 | | 单位 | 陈西铭 | 博时基金管理有限公司 | 基金经理 | | 时间 | 2022 年 7 月 ...

浙江迦南科技股份有限公司 2022 年第三季度报告 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 浙江迦南科技股份有限公司 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 证券代码：300412 证券简称：迦南科技 公告编号：2022-075 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 263,415,006.40 | -17.79% | 757,246,151.42 | 0.65% | | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥493,831,145.02, representing a 14.33% increase compared to ¥431,933,108.57 in the same period last year[21]. - The net profit attributable to shareholders was ¥42,364,338.38, up 12.63% from ¥37,613,929.72 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥39,491,076.83, reflecting a 19.86% increase from ¥32,947,444.33 year-on-year[21]. - The net cash flow from operating activities was -¥39,524,231.35, a decline of 115.00% compared to -¥18,383,617.16 in the previous year[21]. - The total assets at the end of the reporting period were ¥2,489,395,163.35, an increase of 7.61% from ¥2,313,379,679.81 at the end of the previous year[21]. - The net assets attributable to shareholders increased by 2.19% to ¥1,156,679,410.31 from ¥1,131,882,953.25 at the end of the previous year[21]. - Basic earnings per share decreased by 40% to ¥0.09 from ¥0.15 in the previous year, primarily due to an increase in total share capital following the profit distribution[21]. - The weighted average return on net assets was 3.67%, down from 4.43% in the previous year[21]. - The gross profit margin for the pharmaceutical equipment sector was 34.96%, with a decrease of 5.49% compared to the previous year[51]. - The company reported a net profit of 15,954,405.98 CNY from Shanghai Kaixian, contributing significantly to overall performance[85]. - The intelligent warehousing subsidiary incurred a net loss of 7,432,249.46 CNY, indicating challenges in this segment[85]. - The pharmaceutical equipment subsidiary generated a revenue of 67,185,682.54 CNY, with a net profit of 11,422,343.79 CNY, showcasing strong performance[85]. Cash Flow and Investments - The net cash flow from operating activities decreased by 115.00% to -¥39,524,231.35, primarily due to increased payments related to business expansion[49]. - The net cash flow from financing activities increased by 156.80% to ¥37,452,119.44, mainly due to reduced bank financing repayments and dividends compared to the previous year[49]. - The total investment during the reporting period was ¥21,500,000, marking a 100% increase compared to the previous year[60]. - The company reported a fair value change gain of ¥467,768.71, contributing 0.83% to the total profit[54]. - The company has committed to several projects, including an intelligent logistics system with a total investment of ¥18,000 million, which is currently under construction[68]. - The pharmaceutical liquid system project has a total investment of ¥12,000 million, with cumulative investment reaching ¥11,986 million, achieving 99.89% of the expected progress[68]. - The upgrade and expansion of the pharmaceutical R&D service platform has a total investment of ¥5,000 million, with cumulative investment at ¥4,200 million, achieving 84.00% of the expected progress[68]. - The headquarters construction project has a total investment of ¥5,000 million, with cumulative investment fully utilized at 100%[68]. Market Position and Strategy - The company operates in the pharmaceutical equipment sector, providing integrated solutions for oral solid dosage intelligent factories, with a focus on high-end generic drugs and biopharmaceuticals[29]. - The company anticipates continued growth driven by the expansion of high-end generic drug production and the rapid development of the biopharmaceutical and logistics industries[30]. - The company has established a comprehensive pharmaceutical research and testing system through its subsidiary, Bixun Pharmaceutical, to support its service capabilities[30]. - The company has accumulated a large customer base primarily consisting of high-quality pharmaceutical enterprises, covering all regions in China except Taiwan and Macau, and extending to over 30 countries globally[38]. - The company has established a full product service research chain, integrating information consulting, pharmaceutical research, equipment support, and clinical trials, enhancing its comprehensive service capabilities[39]. - The company is positioned as a leading supplier of overall solutions for intelligent factories of oral solid dosage forms in China, with a focus on high-end generic drug solid dosage forms and biopharmaceutical innovation[40]. - The company is expected to benefit from favorable industry policies that support the pharmaceutical equipment manufacturing sector, enhancing its long-term growth prospects[38]. - The company has a strong market position due to its ability to provide high-value integrated equipment solutions and excellent service reputation, which are key drivers of its performance[38]. Research and Development - Research and development investment increased to ¥31,644,830.64, up 13.58% from the previous year, reflecting the company's commitment to new product and technology development[49]. - The company has established long-term stable relationships with major clients, including leading pharmaceutical companies, enhancing customer retention and market barriers[42]. - The company is actively exploring and establishing successful models of industry-university-research cooperation with several universities, enhancing its R&D capabilities[41]. - The company aims to enhance its service capabilities in drug information consulting, pharmaceutical research, pharmaceutical technology equipment, clean engineering support, and clinical trials through both organic and external growth strategies[39]. - The company has a structured profit distribution plan that prioritizes cash dividends when conditions are met[108]. Corporate Governance and Compliance - The company adheres to relevant laws and regulations, ensuring timely and accurate information disclosure to investors[104]. - The company has established a multi-tier governance structure, including a shareholders' meeting, board of directors, supervisory board, and management team[194]. - The company has implemented a comprehensive human resources management system, focusing on employee training and welfare[103]. - The company is currently fulfilling its commitments to shareholders without any delays[109]. - The company has not reported any changes in accounting policies or prior period error corrections during the reporting period[190]. Risks and Challenges - The company operates in the pharmaceutical equipment manufacturing industry, which is supported by national policies, but faces risks from potential changes in industry regulations and market demand[88]. - The domestic pharmaceutical equipment market is highly competitive, with significant pressure from both local and international manufacturers, particularly in the solid dosage equipment sector[89]. - There are risks associated with project funding and execution, as macroeconomic conditions and market dynamics may affect the expected outcomes of investment projects[91]. - The company faces integration risks as it expands through acquisitions, necessitating the alignment of governance structures and operational standards across subsidiaries[92]. Shareholder Information - The total number of shares increased from 292,798,022 to 497,756,637 after a capital reserve conversion and cash dividend distribution, with a cash dividend of CNY 0.6 per share totaling CNY 17.57 million[141]. - The largest shareholder, Canaan Technology Group, holds 19.68% of the shares, totaling 97,972,700 shares[147]. - The company has not conducted any repurchase agreements among the top 10 shareholders during the reporting period[148]. - The company reported a dilution effect on net assets per share due to the implementation of the profit distribution plan[143]. - The company plans to distribute at least 20% of its distributable profits as cash dividends if it is profitable and has positive retained earnings[108].

浙江迦南科技股份有限公司 2022 年第一季度报告全文 证券代码：300412 证券简称：迦南科技 公告编号：2022-038 浙江迦南科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 210,175,206.49 | 167,967,018.60 | 25.13% | | 归属于上市公司股东的净利润（元） | 18,094,190.28 | 10,757, ...